Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis, a Multicenter Randomized Controlled Trial
Peking University First Hospital
176 participants
Jun 15, 2023
INTERVENTIONAL
Conditions
Summary
This is a multicenter randomized, placebo-controlled trial of Vitamin D supplementation in patients on peritoneal dialysis to determine whether oral administration of vitamin D3 after curing an episode of peritonitis could reduce the risk of subsequent peritoneal dialysis-related peritonitis.
Eligibility
Inclusion Criteria4
- Medically stable and receiving peritoneal dialysis for > 1 month
- Older than 18 years old
- Serum 25(OH)D < 30ng/ml
- Adequate dialysis on evaluation with weekly Kt/V ≥ 1.5, or (revised time: 2023-7-11) without clinical uremic symptoms
Exclusion Criteria9
- Receive Vitamin D2/D3 during the previous 1 month (revised time: 2023-7-11) ;
- History of allergic reaction to Cholecalciferol;
- Current or past malignant disease, active hepatitis or hepatic failure, active autoimmune disease, severe digestive malabsorption or an eating disorder, HIV/AIDS;
- Acute systemic infection, cardiovascular disease, surgery, or trauma in the last month;
- A high probability of receiving a kidney transplant or transferring to hemodialysis or drop-out due to socioeconomic causes within 6 months;
- History of kidney transplant;
- Hemodialysis combined with peritoneal dialysis currently;
- Pregnant or breastfeeding;
- Not suitable enrolled assessed by researchers, including patients who could not regular follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in the intervention group will receive oral cholecalciferol 4000U per day.
Patients in the control group will receive placebo 2 capsules per day.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05860270